Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1Breast 1

Conditions

Neuroblastoma 8Prostatic Neoplasms 3Precancerous Conditions 3Glioma 3Astrocytoma 3Adenomatous Polyposis Coli 3Skin Neoplasms 2Sarcoma, Ewing 2Osteosarcoma 2Glioblastoma 2Colorectal Neoplasms 2Carcinoma, Basal Cell 2Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Rhabdoid Tumor 1Osteosarcoma Recurrent 1Oligodendroglioma 1Non-melanoma Skin Cancer 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Melanoma 1Medulloblastoma 1Lymphoma, Follicular 1Lung Neoplasms 1Keratosis, Actinic 1Gastritis, Atrophic 1Esophageal Neoplasms 1Diffuse Intrinsic Pontine Glioma 1

Interventions

pembrolizumab 287Nivolumab 258Ipilimumab 236Cyclophosphamide 135aldesleukin 134Interleukin-2 104Temozolomide 75Dacarbazine 74trametinib 70Vemurafenib 69fludarabine 68dabrafenib 65fludarabine phosphate 62sargramostim 44binimetinib 44Radiosurgery 44Biopsy 43Paclitaxel 42Bevacizumab 42incomplete Freund's adjuvant 39encorafenib 37Radiotherapy 36Cisplatin 36CTLA-4 Antigen 36atezolizumab 35Carboplatin 35Magnetic Resonance Spectroscopy 33cobimetinib 32Specimen Handling 31Introns 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Melanoma × Eflornithine × Clear all
NCT07287917 2026-05-12

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

Aminex Therapeutics, Inc.

Phase 1/2 Recruiting
92 enrolled
BreastDermatologic

Breast Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡